JP2010514722A5 - - Google Patents

Download PDF

Info

Publication number
JP2010514722A5
JP2010514722A5 JP2009543400A JP2009543400A JP2010514722A5 JP 2010514722 A5 JP2010514722 A5 JP 2010514722A5 JP 2009543400 A JP2009543400 A JP 2009543400A JP 2009543400 A JP2009543400 A JP 2009543400A JP 2010514722 A5 JP2010514722 A5 JP 2010514722A5
Authority
JP
Japan
Prior art keywords
cd95l
soluble
cd95r
incorporated
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009543400A
Other languages
English (en)
Japanese (ja)
Other versions
JP5558828B2 (ja
JP2010514722A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2007/011461 external-priority patent/WO2008080623A2/en
Publication of JP2010514722A publication Critical patent/JP2010514722A/ja
Publication of JP2010514722A5 publication Critical patent/JP2010514722A5/ja
Application granted granted Critical
Publication of JP5558828B2 publication Critical patent/JP5558828B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009543400A 2006-12-28 2007-12-28 インビボでの神経膠芽腫細胞の浸潤を阻害するcd95活性の中和 Expired - Fee Related JP5558828B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87736706P 2006-12-28 2006-12-28
US60/877,367 2006-12-28
PCT/EP2007/011461 WO2008080623A2 (en) 2006-12-28 2007-12-28 Neutralization of cd95 activity blocks invasion of glioblastoma cells in vivo

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014116401A Division JP5893078B2 (ja) 2006-12-28 2014-06-05 インビボでの神経膠芽腫細胞の浸潤を阻害するcd95活性の中和

Publications (3)

Publication Number Publication Date
JP2010514722A JP2010514722A (ja) 2010-05-06
JP2010514722A5 true JP2010514722A5 (enExample) 2013-03-28
JP5558828B2 JP5558828B2 (ja) 2014-07-23

Family

ID=39400900

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009543400A Expired - Fee Related JP5558828B2 (ja) 2006-12-28 2007-12-28 インビボでの神経膠芽腫細胞の浸潤を阻害するcd95活性の中和
JP2014116401A Expired - Fee Related JP5893078B2 (ja) 2006-12-28 2014-06-05 インビボでの神経膠芽腫細胞の浸潤を阻害するcd95活性の中和

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014116401A Expired - Fee Related JP5893078B2 (ja) 2006-12-28 2014-06-05 インビボでの神経膠芽腫細胞の浸潤を阻害するcd95活性の中和

Country Status (12)

Country Link
US (2) US9309320B2 (enExample)
EP (2) EP2428252B1 (enExample)
JP (2) JP5558828B2 (enExample)
AU (1) AU2007341631B9 (enExample)
CA (1) CA2673868C (enExample)
CY (1) CY1116006T1 (enExample)
DK (2) DK2101877T3 (enExample)
ES (2) ES2523992T3 (enExample)
PL (2) PL2428252T3 (enExample)
PT (2) PT2428252E (enExample)
SI (1) SI2428252T1 (enExample)
WO (1) WO2008080623A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2963124C (en) 2007-07-10 2019-10-15 Apogenix Ag Tnf superfamily collectin fusion proteins
EP2318441A2 (en) * 2008-07-14 2011-05-11 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Use of cd95 inhibitors for the treatment of inflammatory disorders
US8664366B2 (en) 2009-01-09 2014-03-04 Apogenix Gmbh Fusion proteins forming trimers
EP2456468A1 (en) * 2009-07-21 2012-05-30 Queen Mary and Westfield College Fas (apo-1, cd95) targeted platforms for intracellular drug delivery
EP2322927A1 (en) * 2009-11-16 2011-05-18 Deutsches Krebsforschungszentrum Compounds inhibiting CD95 signaling for the treatment of pancreatic cancer
HK1207095A1 (en) * 2012-07-18 2016-01-22 阿珀吉尼科斯股份公司 Composition comprising a mixture of cd95-fc isoforms
EP2894472A4 (en) * 2012-09-05 2016-03-30 Jsr Corp METHOD OF SCREENING MATERIAL FOR EPITHELIAL CONSERVATION OF CELLS
BR112015027249A2 (pt) * 2013-04-29 2017-09-26 Apogenix Gmbh método de diagnóstico de câncer
US20160115237A1 (en) 2013-05-24 2016-04-28 The University Of British Columbia Cell senescence markers as diagnostic and therapeutic targets
EP3094744A1 (en) * 2014-01-15 2016-11-23 Apogenix AG Method of predicting the responsiveness of a cancer disease to treatment on the basis of dna methylation
EP3137909B1 (en) * 2014-04-29 2018-06-06 Apogenix AG Diagnostic anti-cd95l antibody
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
AU2019403393A1 (en) * 2018-12-20 2021-08-05 The University Of Chicago Methods and compositions related to therapeutic peptides for cancer therapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891434A (en) 1991-06-17 1999-04-06 Centocor, Inc. Monoclonal antibodies to the APO-1 antigen
CA2109398A1 (en) 1992-10-30 1994-05-01 Alejandro A. Aruffo Extracellular matrix receptor ligands that modulate leukocyte function
JPH08127594A (ja) 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Fas抗原に結合する新規蛋白質およびそれをコードするDNA
DE4447484C2 (de) 1994-04-08 1997-07-17 Deutsches Krebsforsch Mittel zur Hemmung von Apoptose
US6060238A (en) * 1995-02-13 2000-05-09 The Regents Of The University Of Michigan Method and composition for regulating apoptosis
DE69636170T2 (de) 1995-03-20 2006-11-02 Okumura, Ko Monoklonaler antikörper, der spezifisch mit dem fas-liganden reagiert, und verfahren zu seiner herstellung
JP3925663B2 (ja) 1995-06-30 2007-06-06 持田製薬株式会社 抗Fasリガンド抗体および該抗体を用いた測定法
JPH09124509A (ja) 1995-10-27 1997-05-13 Sumitomo Electric Ind Ltd 肝炎治療剤
ATE299936T1 (de) 1996-05-02 2005-08-15 Mochida Pharm Co Ltd Fas antigen-derivate
EP1642908A2 (en) 1996-09-02 2006-04-05 Okumura, Ko Apoptosis-induced site from fas ligand
ATE393222T1 (de) 1997-09-18 2008-05-15 Genentech Inc Dcr3 polypeptid, ein tnfr homolog
CA2324517A1 (en) 1998-03-30 1999-10-07 Eli Lilly And Company Therapeutic applications of mature flint (mflint) polypeptides or opg3, a member of the tnf receptor superfamily
US6348573B1 (en) * 1998-04-27 2002-02-19 The Regents Of The University Of Michigan Compositions and methods for identifying apoptosis signaling pathway inhibitors and activators
US6846637B1 (en) 1998-06-18 2005-01-25 Imed Ab Fas peptides and antibodies for modulating apoptosis
US20030170244A1 (en) * 2001-12-21 2003-09-11 Pluenneke John D. Inhibition of Fas signaling
WO2003088975A1 (en) * 2002-04-17 2003-10-30 The Burnham Institute Inhibition of fatty acid synthase by beta-lactones and other compounds for inhibition of cellular proliferation
EP1447093A1 (en) 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
JP2007533595A (ja) * 2003-03-26 2007-11-22 アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウィルス感染の治療
US7445794B1 (en) * 2004-04-29 2008-11-04 The Regents Of The University Of Colorado Methods for treating human proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors

Similar Documents

Publication Publication Date Title
JP2010514722A5 (enExample)
WO2010010466A3 (en) Neutralizing anti-influenza a virus antibodies and uses thereof
WO2008097461A3 (en) Hepcidin and hepcidin antibodies
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
WO2006099875A8 (en) Antibodies against cd38 for treatment of multiple myeloma
WO2009002947A3 (en) Compounds and peptides that bind the trail receptor
WO2009083009A3 (en) Monoclonal antibodies against cd32b
EP2578600A3 (en) RSV-specific binding molecules and means for producing them
WO2006099698A3 (en) Novel anti-plgf antibody
WO2007033230A3 (en) Anti-cd3 antibody formulations
WO2011147982A3 (en) Monoclonal antibodies against her2 epitope
NZ592054A (en) Dengue virus neutralizing antibodies and uses thereof
DK1933871T3 (da) Humane monoklonale antistoffer mod activin-receptor-lignende kinase-1
WO2007129895A3 (en) Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody
EP2360169A3 (en) PSMA antibodies
EP3539988A3 (en) Monoclonal antibodies against her2
WO2010066803A3 (en) Human antibodies against human tissue factor
WO2006128103A3 (en) Humanized anti-cd40 antibodies and their methods of use
WO2008070344A3 (en) Compositions and methods for binding sphingosine-1-phosphate
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
LT2842968T (lt) Humanizuoti anti-il-6 antikūnai, kompozicijos, būdai ir panaudojimas
UA104587C2 (ru) Моноклональное антитело и способ его применения
HK1200464A1 (en) Immunobinders directed against tnf
WO2009081285A3 (en) Hepatitis c virus antibodies
WO2008048519A3 (en) Antibodies that bind cxcr7 epitopes